A randomized, double-blind, placebo-controlled, Phase 2 study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with nonsquamous non-small cell lung cancer who have progressed on immunotherapy
DISEASE:
Non-Small Cell Lung Cancer (NSCLC)
SUMMARY:
This study is to evaluate the combination of inupadenant and carboplatin and pemetrexed for the treatment of NSCLC. Even though both carboplatin and pemetrexed have FDA approval, neither inupadenant nor this combination of drugs have been approved by the FDA. This combination is considered experimental.
Inupadenant alone, inupadenant in combination with a drug that helps cells of the immune system attack cancer cells (pembrolizumab), and inupadenant in combination with chemotherapy drugs (carboplatin and paclitaxel) are being used in an ongoing study, different from the study described here. Currently, the other ongoing study shows that inupadenant given alone, or in combination with pembrolizumab, or in combination with chemotherapy drugs (carboplatin and paclitaxel) is generally well tolerated by participants.
Adenosine, which can build up in and around tumors, binds to cells that are part of your body’s defense system, and prevent them from killing cancer cells. Inupadenant is a drug that binds up the receptors for adenosine and allows immune system cells to stay active.
Carboplatin is a chemotherapy drug that destroys rapidly dividing cells, including cancer cells. It is often used in combination with similar chemotherapy drugs to treat NSCLC after the first therapy has either not worked or stopped working. In recent years, carboplatin has been used in combination with pemetrexed, which blocks the important vitamin, folate. Use of the two together has shown increased survival and fewer side effects than previous combinations.
If you would like more information please call PCSRI at 717-334-4033 ext 131, 148, or 149, or email research@pcsri.com.
